PMID: 9449256Feb 4, 1998Paper

Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group

Antimicrobial Agents and Chemotherapy
M Wolff

Abstract

In an international, multicenter, open-label, randomized comparative study, adult patients in intensive care units were enrolled to receive cefpirome intravenously at 2 g twice daily or ceftazidime intravenously at 2 g three times daily for the empiric treatment of pneumonia. Randomization was performed after a double stratification according to the investigator's initial choice of monotherapy or combination therapy and then on the basis of the severity of disease. The primary endpoint was the clinical response at the end of treatment in the intent-to-treat population. Data for all patients were reviewed by a blinded observer. Of the 400 enrolled patients, 201 received cefpirome (monotherapy, 56%) and 199 received ceftazidime (monotherapy, 51%). Pneumonia was hospital acquired for 75% of the patients. Clinical failures rates were 34 versus 36% (odds ratio = 0.922; upper bound of 90% confidence interval = 1.301) in the intent-to-treat analysis for cefpirome and ceftazidime, respectively. For the cefpirome and ceftazidime groups, there were 35 versus 30% clinical failures among monotherapy-stratified patients, respectively, and 34 versus 42% clinical failures among combination therapy-stratified patients, respectively. The rates ...Continue Reading

References

Nov 1, 1984·Critical Care Medicine·J R Le GallD Villers
May 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinC Grassi
Aug 1, 1994·American Journal of Respiratory and Critical Care Medicine·M S NiedermanW Summer
Apr 1, 1996·Chest·S Crouch BrewerK V Leeper
Jul 1, 1996·American Journal of Respiratory and Critical Care Medicine·L PapazianF Gouin

❮ Previous
Next ❯

Citations

Jul 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H KollefJohn Segreti
Nov 16, 2004·Critical Care Medicine·Pierre-Yves BochudThierry Calandra
Oct 13, 2006·Current Opinion in Infectious Diseases·L E Nicolle
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ioannis A BliziotisMatthew E Falagas
Jan 16, 2002·American Journal of Respiratory and Critical Care Medicine·Harald HerknerMarkus Müller
Mar 13, 2002·Critical Care Medicine·Philippe MontraversJean Louis Pourriat
Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
Sep 5, 2012·Expert Opinion on Pharmacotherapy·Sang-Ho Choi, Younsuck Koh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.